BRK-B vs JMSB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
JMSB presents a strong value opportunity, trading significantly below both its Graham Number ($25.09) and estimated Intrinsic Value ($43.95). While the Piotroski F-Score of 4/9 indicates stable but not exceptional financial health, the company demonstrates robust growth with earnings increasing 26.3% YoY. The valuation is attractive with a P/E of 13.93 and a low Price/Book of 1.11. Despite a heavily bearish technical trend (10/100), the fundamental divergence suggests a potential buying opportunity for long-term investors.
Compare Another Pair
Related Comparisons
BRK-B vs JMSB: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and John Marshall Bancorp, Inc. (JMSB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.